NASDAQ:PTI - Proteostasis Therapeutics Stock Price, Forecast & News

Proteostasis Therapeutics trades on the NASDAQ under the ticker symbol "PTI."

Proteostasis Therapeutics Inc (NASDAQ:PTI) issued its quarterly earnings results on Thursday, November, 7th. The company reported ($0.25) earnings per share for the quarter, beating analysts' consensus estimates of ($0.40) by $0.15. View Proteostasis Therapeutics' Earnings History.

Proteostasis Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 13th 2020. View Earnings Estimates for Proteostasis Therapeutics.

4 brokers have issued 12 month price objectives for Proteostasis Therapeutics' stock. Their forecasts range from $4.00 to $14.00. On average, they anticipate Proteostasis Therapeutics' share price to reach $7.50 in the next year. This suggests a possible upside of 387.0% from the stock's current price. View Analyst Price Targets for Proteostasis Therapeutics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Proteostasis Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Proteostasis Therapeutics.

News headlines about PTI stock have been trending positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Proteostasis Therapeutics earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Proteostasis Therapeutics.

Proteostasis Therapeutics saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 4,910,000 shares, a decrease of 5.4% from the January 15th total of 5,190,000 shares. Based on an average daily volume of 5,673,000 shares, the days-to-cover ratio is currently 0.9 days. Approximately 11.8% of the company's stock are sold short. View Proteostasis Therapeutics' Current Options Chain.

Some companies that are related to Proteostasis Therapeutics include Corbus Pharmaceuticals (CRBP), CytomX Therapeutics (CTMX), Concert Pharmaceuticals (CNCE), Verrica Pharmaceuticals (VRCA), Stemline Therapeutics (STML), Evolus (EOLS), Lexicon Pharmaceuticals (LXRX), Spectrum Pharmaceuticals (SPPI), MannKind (MNKD), Albireo Pharma (ALBO), Syndax Pharmaceuticals (SNDX), Minerva Neurosciences (NERV), Syros Pharmaceuticals (SYRS), Bicycle Therapeutics (BCYC) and Evofem Biosciences (EVFM).

Based on aggregate information from My MarketBeat watchlists, some companies that other Proteostasis Therapeutics investors own include BHP Group (BHP), Idera Pharmaceuticals (IDRA), Micron Technology (MU), Rite Aid (RAD), Clearside Biomedical (CLSD), Amarin (AMRN), vTv Therapeutics (VTVT), Syndax Pharmaceuticals (SNDX), Sorrento Therapeutics (SRNE) and Agile Therapeutics (AGRX).

(PTI) raised $51 million in an initial public offering on Thursday, February 11th 2016. The company issued 3,900,000 shares at a price of $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers.

Proteostasis Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Bain Capital Public Equity Management II LLC (1.45%), Oxford Asset Management LLP (0.97%), Acadian Asset Management LLC (0.52%), Connor Clark & Lunn Investment Management Ltd. (0.21%), 9258 Wealth Management LLC (0.04%) and National Asset Management Inc. (0.03%). Company insiders that own Proteostasis Therapeutics stock include Enterprise Associates 12 New, Franklin M Berger, Meenu Chhabra and Po Shun Lee. View Institutional Ownership Trends for Proteostasis Therapeutics.

PTI stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC and Virtu Financial LLC. View Insider Buying and Selling for Proteostasis Therapeutics.

PTI stock was bought by a variety of institutional investors in the last quarter, including Bain Capital Public Equity Management II LLC, Oxford Asset Management LLP, Connor Clark & Lunn Investment Management Ltd., 9258 Wealth Management LLC and National Asset Management Inc.. View Insider Buying and Selling for Proteostasis Therapeutics.

Shares of PTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PTI stock can currently be purchased for approximately $1.54.

Proteostasis Therapeutics has a market capitalization of $78.74 million and generates $2.84 million in revenue each year. The company earns $-61,830,000.00 in net income (profit) each year or ($1.61) on an earnings per share basis. Proteostasis Therapeutics employs 48 workers across the globe.View Additional Information About Proteostasis Therapeutics.

The official website for Proteostasis Therapeutics is http://www.proteostasis.com/.

Proteostasis Therapeutics' mailing address is 80 Guest Street Suite 500, Boston MA, 02135. The company can be reached via phone at 617-225-0096 or via email at [email protected]